Research programme: mTOR-protein-modulator therapeutics - Mount Tam/Isomerase

Drug Profile

Research programme: mTOR-protein-modulator therapeutics - Mount Tam/Isomerase

Latest Information Update: 19 Jan 2017

Price : $50

At a glance

  • Originator Mount Tam Biotechnologies
  • Developer Isomerase Therapeutics; Mount Tam Biotechnologies
  • Class
  • Mechanism of Action MTOR protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Research Unspecified

Most Recent Events

  • 09 Jan 2017 Early research in Undefined indication in USA
  • 09 Jan 2017 Mount Tam and Isomerase Therapeutics agree to develop mTOR-protein-modulator therapeutics for Undefined indication in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top